POINT Biopharma is developing radiopharmaceutical products for cancer treatment. Radioligands are microscopic, cancer-seeking missiles that are actively used to diagnose and treat cancers such as non-Hodgkins lymphoma, neuroendocrine tumors and prostate cancer. Unlike chemotherapy that can cause extensive damage to healthy tissues and organs, radioligands precisely deliver radiation to tumors, damaging only the cancer cells. POINT is committed to accelerating the discovery, development and global access to their life-changing radioligand therapies - their lead program, SPLASH, is in Phase 3 clinical stages for treating prostate cancer.

POINT Biopharma

Founded: 2020
Location: Indianapolis, IN
Employee range: 50 - 200
Clinical stage: Clin3
Therapy area: Neuroendocrine tumors
Drug types: ONC
Lead product: PNT2003
Funding: $165M Jun 2021

Drug notes:

About:

Jobs: